Bioventus Receives 501(k) Clearance for StimRouter Pain Management Device
On March 1, 2022, the US Food and Drug Administration (FDA) gave Bioventus' StimRouter Neuromodulation System 510(k) approval. The next-generation pain treatment device is intended to treat chronic pain caused by peripheral nerves, excluding craniofacial pain. StimRouter is a minimally invasive device that includes an implanted thin lead with a conductive electrode, the StimRouter Plus Mobile Application, and an external electric field conductor (E-EFC).
Bioventus chief commercial officer John Nosenzo commented, “The impact of chronic, debilitating pain is more than just managing...
